Compare Crispr Therapeutics AG (CRSP) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PPG Industries, Inc. — how do they compare? Crispr Therapeutics AG trades at $54.3 (market cap $5.23B), while PPG Industries, Inc. trades at $116.16 (market cap $25.82B). The key difference: PPG Industries, Inc. is far larger — about 4.9× Crispr Therapeutics AG's market cap, and PPG Industries, Inc. pays a 2.55% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PPG | |
|---|---|---|
Market Cap | $5.23B | $25.82B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $131.56 |
52-Week Low | $44.34 | $94.34 |
Enterprise Value | $3.65B | $31.69B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
PPG Industries trades at $115.47, down 3.55% amid bearish technical signals, though fundamentals show resilience with Q2 2026 sales up 7% year-over-year and a 4.2% dividend hike in July 2026. The stock's valuation appears reasonable with a P/E of 16.67 and P/S of 1.59, while profitability metrics like a 9.57% net margin and 19.63% ROE support operational strength. Recent leadership changes in Industrial Coatings and FTSE4Good recognition highlight ongoing corporate developments.
Wall Street maintains a bullish stance with 55% buy ratings and a $129.17 consensus target, implying 12% upside, but near-term risks include raw material cost pressures and mixed earnings performance. The technical bearish signal and proximity to support at $114 suggest cautious entry points, while the dividend aristocrat status and solid cash flow provide downside protection for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
